Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options)

Kenna D. Payne; Amrita Das; Michelle Ndiulor; Ronald G. Hall

doi:10.1080/17512433.2018.1411800

Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options)

Kenna D. Payne, Amrita Das, Michelle Ndiulor, Ronald G. Hall

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a problematic pathogen in both outpatient and inpatient settings. Research to optimize the dosing of these agents is needed to slow the development of antimicrobial resistance and to decrease the likelihood of clinical failure. Areas covered: This review summarizes the available data for orally administered antimicrobials routinely used as monotherapy for MRSA infections. We make recommendations and highlight the current gaps in the literature. A PubMed (1966–Present) search was performed to identify relevant literature for this review. Expert commentary: There is a vast divide in the amount of pharmacokinetic/pharmacodynamic data to guide dosing decisions for older MRSA agents compared with the oxazolidenones. Five-year view: Additional retrospective data will become available for the older MRSA agents in severe MRSA infections.

Original language	English
Pages (from-to)	139-149
Number of pages	11
Journal	Expert Review of Clinical Pharmacology
Volume	11
Issue number	2
DOIs	https://doi.org/10.1080/17512433.2018.1411800
State	Published - 1 Feb 2018

Keywords

antimicrobial
Dose optimization
MRSA
pharmacodynamics
pharmacokinetics

Access to Document

10.1080/17512433.2018.1411800

Cite this

@article{3cf194264e6841a2bc1c60338cf7b1ce,

title = "Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options)",

abstract = "Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a problematic pathogen in both outpatient and inpatient settings. Research to optimize the dosing of these agents is needed to slow the development of antimicrobial resistance and to decrease the likelihood of clinical failure. Areas covered: This review summarizes the available data for orally administered antimicrobials routinely used as monotherapy for MRSA infections. We make recommendations and highlight the current gaps in the literature. A PubMed (1966–Present) search was performed to identify relevant literature for this review. Expert commentary: There is a vast divide in the amount of pharmacokinetic/pharmacodynamic data to guide dosing decisions for older MRSA agents compared with the oxazolidenones. Five-year view: Additional retrospective data will become available for the older MRSA agents in severe MRSA infections.",

keywords = "antimicrobial, Dose optimization, MRSA, pharmacodynamics, pharmacokinetics",

author = "Payne, {Kenna D.} and Amrita Das and Michelle Ndiulor and Hall, {Ronald G.}",

note = "Funding Information: RG Hall 2nd discloses: Advisory board (Genentech), Grant funding (Merck). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose. Publisher Copyright: {\textcopyright} 2017 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2018",

month = feb,

day = "1",

doi = "10.1080/17512433.2018.1411800",

language = "English",

volume = "11",

pages = "139--149",

journal = "Expert Review of Clinical Pharmacology",

issn = "1751-2433",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options)

AU - Payne, Kenna D.

AU - Das, Amrita

AU - Ndiulor, Michelle

AU - Hall, Ronald G.

N1 - Funding Information: RG Hall 2nd discloses: Advisory board (Genentech), Grant funding (Merck). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose. Publisher Copyright: © 2017 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a problematic pathogen in both outpatient and inpatient settings. Research to optimize the dosing of these agents is needed to slow the development of antimicrobial resistance and to decrease the likelihood of clinical failure. Areas covered: This review summarizes the available data for orally administered antimicrobials routinely used as monotherapy for MRSA infections. We make recommendations and highlight the current gaps in the literature. A PubMed (1966–Present) search was performed to identify relevant literature for this review. Expert commentary: There is a vast divide in the amount of pharmacokinetic/pharmacodynamic data to guide dosing decisions for older MRSA agents compared with the oxazolidenones. Five-year view: Additional retrospective data will become available for the older MRSA agents in severe MRSA infections.

AB - Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a problematic pathogen in both outpatient and inpatient settings. Research to optimize the dosing of these agents is needed to slow the development of antimicrobial resistance and to decrease the likelihood of clinical failure. Areas covered: This review summarizes the available data for orally administered antimicrobials routinely used as monotherapy for MRSA infections. We make recommendations and highlight the current gaps in the literature. A PubMed (1966–Present) search was performed to identify relevant literature for this review. Expert commentary: There is a vast divide in the amount of pharmacokinetic/pharmacodynamic data to guide dosing decisions for older MRSA agents compared with the oxazolidenones. Five-year view: Additional retrospective data will become available for the older MRSA agents in severe MRSA infections.

KW - antimicrobial

KW - Dose optimization

KW - MRSA

KW - pharmacodynamics

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85041231566&partnerID=8YFLogxK

U2 - 10.1080/17512433.2018.1411800

DO - 10.1080/17512433.2018.1411800

M3 - Review article

C2 - 29186999

AN - SCOPUS:85041231566

SN - 1751-2433

VL - 11

SP - 139

EP - 149

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

IS - 2

ER -

Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options)

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this